Drug Profile


Alternative Names: Anti-beta amyloid monoclonal antibody - Biogen Idec; BART; BIIB 037; NI-10

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Biogen
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 08 Dec 2016 Interim efficacy and adverse events data from a phase Ib trial in Alzheimer's disease released by Biogen
  • 01 Dec 2016 Biogen completes a phase I trial in Alzheimer's disease (Early-stage disease, Mid-stage disease) in Japan (IV) (NCT02434718)
  • 01 Nov 2016 Biogen completes a phase I bioavailability trial in Healthy volunteers in USA (SC, IV) (NCT02782975)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top